PLAU and hepatocellular carcinoma: Treatment with baicalein reduced the production of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9, and urokinase-type plasminogen activator (u-PA), as well as proteinase activity, in hepatocellular carcinoma MHCC97H cells.